Summary of Significant Accounting Policies (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Apr. 16, 2021
Dec. 17, 2021
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]        
Deferred Revenue [1],[2]     $ 50,500,000
[custom:AccountsReceivablesAmounted-0]     50,640,000 4,000
[custom:AccountsReceivablesAmountedGrants-0]     200,000 61,000
Allowance for Doubtful Accounts, Premiums and Other Receivables     74,000 44,000
Money Market Funds, at Carrying Value     52,300,000 28,800,000
Foreign currency translation adjustments, net of tax     $ 1,544,000 $ 2,986,000
Maximum [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life       10 years
Finite-Lived Intangible Asset, Useful Life       10 years
Minimum [Member]        
Property, Plant and Equipment [Line Items]        
Property, Plant and Equipment, Useful Life     3 years  
Finite-Lived Intangible Asset, Useful Life     5 years  
Collaborative Arrangement [Member]        
Property, Plant and Equipment [Line Items]        
Deferred Revenue       $ 100,000
Collaborative Arrangement [Member] | Maximum [Member]        
Property, Plant and Equipment [Line Items]        
Deferred Revenue     $ 800,000  
Deferred Revenue, Revenue Recognized     800,000  
Collaborative Arrangement [Member] | Minimum [Member]        
Property, Plant and Equipment [Line Items]        
Deferred Revenue     49,700,000  
Deferred Revenue, Revenue Recognized     $ 300,000  
Immunomic Therapeutics Inc [Member] | Collaborative Arrangement [Member]        
Property, Plant and Equipment [Line Items]        
Upfront licensing fees $ 2,000,000.0 $ 50,000,000.0    
Immunomic Therapeutics Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]        
Property, Plant and Equipment [Line Items]        
Upfront licensing fees $ 67,000,000.0 $ 620,000,000.0    
Royalty percentage 10.00%      
[1] Excludes government grants as Lineage has determined government grants are outside the scope of ASU 2014-09 - Revenue from Contracts with Customers (Topic 606).
[2] Increase in accounts receivable due to accrual of $50.0 million upfront payment related to Roche Agreement, offset to deferred revenues.